Cargando…

Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight

Diabetic foot ulcer (DFU) is considered the most catastrophic complication of diabetes mellitus (DM), leading to repeated hospitalizations, infection, gangrene, and finally amputation of the limb. In patients suffering from diabetes mellitus, the wound-healing process is impaired due to various fact...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmoudvand, Golnaz, Karimi Rouzbahani, Arian, Razavi, Zahra Sadat, Mahjoor, Mohamad, Afkhami, Hamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133463/
https://www.ncbi.nlm.nih.gov/pubmed/37122856
http://dx.doi.org/10.3389/fbioe.2023.1158484
_version_ 1785031570391826432
author Mahmoudvand, Golnaz
Karimi Rouzbahani, Arian
Razavi, Zahra Sadat
Mahjoor, Mohamad
Afkhami, Hamed
author_facet Mahmoudvand, Golnaz
Karimi Rouzbahani, Arian
Razavi, Zahra Sadat
Mahjoor, Mohamad
Afkhami, Hamed
author_sort Mahmoudvand, Golnaz
collection PubMed
description Diabetic foot ulcer (DFU) is considered the most catastrophic complication of diabetes mellitus (DM), leading to repeated hospitalizations, infection, gangrene, and finally amputation of the limb. In patients suffering from diabetes mellitus, the wound-healing process is impaired due to various factors such as endothelial dysfunction and synthesis of advanced glycation end-products, hence, conventional therapeutic interventions might not be effective. With increasing therapeutic applications of mesenchymal stem cells (MSCs) in recent years, their potential as a method for improving the wound-healing process has gained remarkable attention. In this field, mesenchymal stem cells exert their beneficial effects through immunomodulation, differentiation into the essential cells at the site of ulcers, and promoting angiogenesis, among others. In this article, we review cellular and molecular pathways through which mesenchymal stem cell therapy reinforces the healing process in non-healing Diabetic foot ulcers.
format Online
Article
Text
id pubmed-10133463
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101334632023-04-28 Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight Mahmoudvand, Golnaz Karimi Rouzbahani, Arian Razavi, Zahra Sadat Mahjoor, Mohamad Afkhami, Hamed Front Bioeng Biotechnol Bioengineering and Biotechnology Diabetic foot ulcer (DFU) is considered the most catastrophic complication of diabetes mellitus (DM), leading to repeated hospitalizations, infection, gangrene, and finally amputation of the limb. In patients suffering from diabetes mellitus, the wound-healing process is impaired due to various factors such as endothelial dysfunction and synthesis of advanced glycation end-products, hence, conventional therapeutic interventions might not be effective. With increasing therapeutic applications of mesenchymal stem cells (MSCs) in recent years, their potential as a method for improving the wound-healing process has gained remarkable attention. In this field, mesenchymal stem cells exert their beneficial effects through immunomodulation, differentiation into the essential cells at the site of ulcers, and promoting angiogenesis, among others. In this article, we review cellular and molecular pathways through which mesenchymal stem cell therapy reinforces the healing process in non-healing Diabetic foot ulcers. Frontiers Media S.A. 2023-04-13 /pmc/articles/PMC10133463/ /pubmed/37122856 http://dx.doi.org/10.3389/fbioe.2023.1158484 Text en Copyright © 2023 Mahmoudvand, Karimi Rouzbahani, Razavi, Mahjoor and Afkhami. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Mahmoudvand, Golnaz
Karimi Rouzbahani, Arian
Razavi, Zahra Sadat
Mahjoor, Mohamad
Afkhami, Hamed
Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight
title Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight
title_full Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight
title_fullStr Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight
title_full_unstemmed Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight
title_short Mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: New insight
title_sort mesenchymal stem cell therapy for non-healing diabetic foot ulcer infection: new insight
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133463/
https://www.ncbi.nlm.nih.gov/pubmed/37122856
http://dx.doi.org/10.3389/fbioe.2023.1158484
work_keys_str_mv AT mahmoudvandgolnaz mesenchymalstemcelltherapyfornonhealingdiabeticfootulcerinfectionnewinsight
AT karimirouzbahaniarian mesenchymalstemcelltherapyfornonhealingdiabeticfootulcerinfectionnewinsight
AT razavizahrasadat mesenchymalstemcelltherapyfornonhealingdiabeticfootulcerinfectionnewinsight
AT mahjoormohamad mesenchymalstemcelltherapyfornonhealingdiabeticfootulcerinfectionnewinsight
AT afkhamihamed mesenchymalstemcelltherapyfornonhealingdiabeticfootulcerinfectionnewinsight